GlobalData

Clinical trials in India also growing at a higher rate, and the country is now in fourth place for COVID-19 trials

COVID-19 may also be disrupting other therapy areas by reducing service agreements for other non-COVID-19 drugs

China's Sinopharm and Sinovac (in collaboration with Brazil-based Butantan) have both reported encouraging results in the early…

According to figures compiled by the CDSCO, India will be producing 20,000 vials per day by the end of July. 

In recent years, Cipla also had agreements with Roche India, Mannkind USA, Stempeutics Research, Novartis and Luye Pharma to…

Two major deals contributed 47 per cent to the total deal value

Experts feel that COVID-19 vaccines should ideally demonstrate an upsurge in both neutralising antibody titres and cell-mediated…

This increase was due to stockpiling by people in preparation for reduced medical access in the lockdown

Despite the recent surge of development within the MDS space, KOLs argue that the level of unmet need remained dire.

As horsepox virus may have been accidentally extirpated there has most likely been no previous exposure to the vector, and any…